Evidence map›Paper›PMID 36300129›Full record

ArticleFrontiers in immunology2022

Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome.

Sabine Gravelsina, Anda Vilmane, Simons Svirskis, Santa Rasa-Dzelzkaleja, Zaiga Nora-Krukle, Katrine Vecvagare, Angelika Krumina, Iana Leineman, Yehuda Shoenfeld, Modra Murovska

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.Health technology assessment (Winchester, England) · 2025
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sabine GravelsinaInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Anda VilmaneInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Simons SvirskisInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Santa Rasa-DzelzkalejaInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Zaiga Nora-KrukleInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Katrine VecvagareInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Angelika KruminaDepartment of Infectology, Rīga Stradiņš University, Riga, Latvia.
Iana LeinemanZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Yehuda ShoenfeldZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Modra MurovskaInstitute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.
Riga Stradiņš University · LVTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that is mainly diagnosed based on its clinical symptoms. Biomarkers that could facilitate the diagnosis of ME/CFS are not yet available; therefore, reliable and clinically useful disease indicators are of high importance. The aim of this work was to analyze the association between ME/CFS clinical course severity, presence of HHV-6A/B infection markers, and plasma levels of autoantibodies against adrenergic and muscarinic acetylcholine receptors. A total of 134 patients with ME/CFS and 33 healthy controls were analyzed for the presence of HHV-6A/B using PCRs, and antibodies against beta2-adrenergic receptors (β2AdR) and muscarinic acetylcholine receptors (M3 AChR and M4 AChR) using ELISAs. HHV-6A/B U3 genomic sequence in whole-blood DNA was detected in 19/31 patients with severe ME/CFS, in 18/73 moderate ME/CFS cases, and in 7/30 mild ME/CFS cases. Severity-related differences were found among those with a virus load of more than 1,000 copies/10

Indexed as

Fatigue Syndrome, ChronicHerpesvirus 6, HumanAdrenergic AgentsAlgorithmsAutoantibodiesBiomarkersDNAHumansReceptors, AdrenergicReceptors, MuscarinicAdrenergic AgentsAutoantibodiesBiomarkersDNAReceptors, AdrenergicReceptors, MuscarinicAChR antibodiesbiomarkersHHV-6ME/CFSβ2AdR antibodies

Identifiers

PMID36300129
PMCPMC9589447
OpenAlexW4303980434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.